Close

Armaron Bio

What

Cardioprotectants

CEO

Grant McLachlan

Investment Director

Michael Panaccio

Investment Date

March 2004
  • Michael and Nick were pivotal to securing further investment from AstraZeneca’s VC arm, and we’re now in a preclinical development program.
    - Grant McLachlan, CEO

Armaron Bio is a life sciences start-up company based in Melbourne. Armaron Bio is developing proprietary lead cardioprotectant and neuroprotectant small molecules to reduce tissue damage following a heart attack or stroke. Its lead compound is presently in Phase I clinical development and will enter a Proof of Concept Phase II trial in 2015.